Pharmascience International Launches pms-Oxybutynin 5 mg in Panama

Pharmascience’s division, Pharmascience International (PSI), is proud to announce the launch of pms-Oxybutynin 5 mg tablets through our strategic partnership with Bioplus in Panama!

pms-Oxybutynin, the generic equivalent of DITROPAN®, is indicated for the relief of symptoms associated with voiding in patients with uninhibited neurogenic bladder and reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria).

“Our strategic partnership with Bioplus further expands our presence in Latin America and supports our commitment to provide high quality medicines at an affordable price,” said Jack Gagnon, Vice-President and General Manager of Pharmascience International.



Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada. Pharmascience delivers high-quality medicines globally in over 50 countries worldwide.

Pharmascience’s products are developed with the highest international regulatory standards in addition to industry best practices and are distributed as FDA certified generic products in the United States. Pharmascience’s global presence and agile business development model provide healthcare communities around the world with the high-quality Canadian medicines to respond to patients’ quality of life needs.

Pharmascience’s R&D team has the extensive expertise necessary for the development of complex injectable and solid oral generic drugs. Pharmascience has invested over $750M in research and development and ranks amongst the top generic manufacturers in Canada, offering over 300 product families, 1,400 stock keeping units (SKUs) in more than 20 dosage forms delivering over 5 billion units in finished dosage forms.

For product information, please contact Pharmascience’s Medical Information Department at 1-888-550-6060.   

DITROPAN® is a registered trademark owned by ALZA CORPORATION

Published in

Product Launches